

22nd September 2025

Circular to All Ferring's Trade Distributors

Dear Business Partners,

Subject: Implementation of Maximum Retail Price (MRP) Revision effective 22nd September 2025

We all know that the GST rates on drugs stand revised downwards to 5% effective September 22, 2025. Consequent to this change, following are mandated in the supply chain of drugs from the effective date.

1. Revision of Product MRPs and Form V Filing

- The downward revision in GST rate mandates a corresponding reduction in the “**Maximum Retail Prices** (MRP). This change is effective from September 22, 2025, at all levels in the supply chain
- As per National Pharmaceuticals Pricing Authority (NPPA) guidelines, revised price notifications under Form V are being filed and will be applicable effective 22nd Sept. 2025
- Trade margins and ITC eligibility for existing stock remain unaffected at all levels in the supply chain

2. Statutory Requirement to Pass on Benefits of reduced MRP

- The benefit of reduced taxes is to be passed on to the end consumer and it is **mandatory under Para 25 of the Drugs (Prices Control) Order, 2013**.
- This benefit should be passed down to the final consumer through the Distributors and Retailers and it applies to even the stocks in their shelves/stores.
- Distributors and Retailers should display Form V or Supplementary Price List in a noticeable place in their premises so that reduced MRP is visible to all the stakeholders.


You are therefore once again requested to:

- Implement the revised MRPs with immediate effect and communicate the same without delay to all Retailers and Wholesalers.
- Ensure that you, along with Retailers and Wholesalers, sell all existing and future stock strictly at the revised MRPs, thereby remaining fully compliant with NPPA's Office Memorandum.
- Draw the attention of Retailers and Wholesalers to Para 24(4) of the DPCO 2013, which mandates that all Retailer and Dealer must display the manufacturer's updated price list at a prominent place in the business premises for easy accessibility to customers.

We thank you for your cooperation and look forward to your continued support.

Warm Regards,
Ferring Pharmaceuticals Pvt. Ltd.


Bhuvan Motta
 Director – Finance & Supply Chain



स्वास्थ्य एवं
परिवार कल्याण मंत्रालय
MINISTRY OF
**HEALTH AND
FAMILY WELFARE**

सत्यमेव जयते

FERRING

PHARMACEUTICALS

GST REFORMS:

Making Healthcare Affordable


Old Rate

12%

New Rate

5%
NIL

GST



Reducing the financial burden
on patients and supporting
long-term treatment in **Fertility,**
Urology, Gastroenterology,
and **Oncology.**

